1528-1167/asset/olbannerleft.gif?v=1&s=bae5cfdb8dec65198cd267c78826e3fef2ef0ede)
The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country
Article first published online: 21 MAR 2008
DOI: 10.1111/j.1528-1167.2008.01579.x
© 2008 International League Against Epilepsy
Additional Information
How to Cite
Picot, M.-C., Baldy-Moulinier, M., Daurès, J.-P., Dujols, P. and Crespel, A. (2008), The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia, 49: 1230–1238. doi: 10.1111/j.1528-1167.2008.01579.x
Publication History
- Issue published online: 4 JUL 2008
- Article first published online: 21 MAR 2008
- Accepted February 4, 2008; Online Early publication March 21, 2008.
- Abstract
- Article
- References
- Cited By
Keywords:
- Epidemiology;
- Epilepsy;
- Prevalence;
- Pharmacoresistance;
- Adult;
- France
Summary
Purpose: To determine the prevalence of epilepsy in a defined adult population and identify the frequency and principal features of pharmacoresistant epilepsy.
Methods: From a population over 15 years of age residing in a medium-sized French city, all patients with epilepsy on June 30, 1995 were identified from multiple sources. Pharmacoresistance was defined as failure to control epilepsy by at least two first-line antiepileptic drugs, with a seizure frequency of at least one per month for 18 months. Collected data were examined by experts in epileptology, and responding patients were reexamined using a standardized diagnostic questionnaire. ILAE definitions and classifications were used.
Results: The age-adjusted prevalence of active epilepsy was 5.4 per 1,000 (95% CI: 4.7–6.0) and was higher for males (7.8) than for females (5.2). For epilepsy in remission under treatment, this rate was 0.7 per 1,000 (95% CI: 0.5–0.95). Age-specific prevalence was highest in age groups 25–49 years and declined in the oldest age groups. Localization-related seizures represented 61.1% of cases and generalized seizures 30.9%. The proportion of noncontrolled epilepsy (seizure-frequency at least one per month for 18 months) was 15.6%, corresponding to a prevalence of 0.94 per 1,000. In this group, the mean age at onset was lower (p = 0.0007) and localization-related epilepsy more frequent (p = 0.01).
Conclusion: The findings support previous epidemiological estimates of the prevalence of epilepsy in developed countries. For approximately one patient in eight, epilepsy was not adequately controlled.